Spironolactone and Hyperkalaemia: is the FAERS signal real?
Spironolactone ↔ Hyperkalaemia
Spironolactone is a mineralocorticoid-receptor antagonist, and potassium retention is not a side effect of the drug so much as a direct extension of how it works: blocking aldosterone in the distal nephron reduces potassium excretion. Hyperkalaemia is therefore an expected, dose-related pharmacological consequence, and it is the principal safety concern when spironolactone is combined with ACE inhibitors, ARBs, or potassium supplements, or used in patients with chronic kidney disease. The landmark RALES trial in severe heart failure showed a survival benefit but also a real increase in serious hyperkalaemia, and the later TOPCAT trial and clinical experience reinforced that potassium must be monitored. This is graded “expected pharmacological effect” rather than a surprise signal — the high count reflects how widely the drug is used rather than an unexpected mechanism.
Regulatory basis: spironolactone prescribing information (hyperkalaemia warning and monitoring). RALES (1999) and TOPCAT (2014) randomized trials.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium rises during exposure and falls after withdrawal |
| Strength | met | PRR 25 on a large co-report count |
| Consistency | met | Seen consistently in trials (RALES, TOPCAT) and in practice |
| Specificity | met | Directly tied to the drug's aldosterone-blocking mechanism |
| Biological gradient | met | Dose-related and worse with renal impairment or added RAAS blockade |
| Plausibility | met | Reduced distal potassium excretion is the intended pharmacology, not an off-target effect |
| Coherence | met | Coheres with the whole mineralocorticoid-antagonist class |
| Experiment | met | Randomized trials (RALES, TOPCAT) with structured potassium monitoring directly address it |
| Analogy | met | Analogous to eplerenone and other potassium-sparing diuretics |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — spironolactone vs placebo in heart failure with preserved ejection fraction (TOPCAT, NCT00094302), N=3,445
| Term (as recorded) | Spironolactone (n=1,722) | Placebo (n=1,723) |
|---|---|---|
| HYPERKALEMIA — renal disorders (serious) | 20 | 5 |
| HYPERKALEMIA — renal disorders (all) | 226 | 96 |
Hyperkalaemia is roughly four times more common on spironolactone, on both serious and total events — direct randomized confirmation of the drug's expected potassium-retaining effect. This is what a genuinely expected pharmacological signal looks like when a trial measures it properly. View on ClinicalTrials.gov →